1
|
Tungsirisurp S, O'Reilly R, Napier R. Nucleic acid aptamers as aptasensors for plant biology. TRENDS IN PLANT SCIENCE 2023; 28:359-371. [PMID: 36357246 DOI: 10.1016/j.tplants.2022.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 09/23/2022] [Accepted: 10/05/2022] [Indexed: 06/16/2023]
Abstract
Our knowledge of cell- and tissue-specific quantification of phytohormones is heavily reliant on laborious mass spectrometry techniques. Genetically encoded biosensors have allowed spatial and some temporal quantification of phytohormones intracellularly, but there is still limited information on their intercellular distributions. Here, we review nucleic acid aptamers as an emerging biosensing platform for the detection and quantification of analytes with high affinity and specificity. Options for DNA aptamer technology are explained through selection, sequencing analysis and techniques for evaluating affinity and specificity, and we focus on previously developed DNA aptamers against various plant analytes. We suggest how these tools might be applied in planta for quantification of molecules of interest both intracellularly and intercellularly.
Collapse
Affiliation(s)
| | - Rachel O'Reilly
- School of Chemistry, University of Birmingham, Birmingham B15 2TT, UK
| | - Richard Napier
- School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.
| |
Collapse
|
2
|
de Freitas Saito R, Barion BG, da Rocha TRF, Rolband A, Afonin KA, Chammas R. Anticoagulant Activity of Nucleic Acid Nanoparticles (NANPs) Assessed by Thrombin Generation Dynamics on a Fully Automated System. Methods Mol Biol 2023; 2709:319-332. [PMID: 37572292 PMCID: PMC10482313 DOI: 10.1007/978-1-0716-3417-2_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023]
Abstract
Rapidly reversible anticoagulant agents have great clinical potential. Oligonucleotide-based anticoagulant agents are uniquely positioned to fill this clinical niche, as they are able to be deactivated through the introduction of the reverse complement oligo. Once the therapeutic and the antidote oligos meet in solution, they are able to undergo isothermal reassociation to form short, inactive, duplexes that are rapidly secreted via filtration by the kidneys. The formation of the duplexes interrupts the structure of the anticoagulant oligo, allowing normal coagulation to be restored. To effectively assess these new anticoagulants, a variety of methods may be employed. The measurement of thrombin generation (TG) reflects the overall capacity of plasma to produce active thrombin and provides a strong contribution to identifying new anticoagulant drugs, including DNA/RNA thrombin binding aptamer carrying fibers which are used through this chapter as an example. Here we describe the TG assessed by Calibrated Automated Thrombogram (CAT) assay in a fully automated system. This method is based on the detection of TG in plasma samples by measuring fluorescent signals released from a quenched fluorogenic thrombin substrate and the subsequent conversion of these signals in TG curves.
Collapse
Affiliation(s)
- Renata de Freitas Saito
- Comprehensive Center for Precision Oncology, Centro de Investigação Translacional em Oncologia (LIM24), Departamento de Radiologia e Oncologia, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil.
| | - Bárbara Gomes Barion
- Laboratório de Hemostasia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
| | - Tania Rubia Flores da Rocha
- Laboratório de Hemostasia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
| | - Alex Rolband
- University of North Carolina, Charlotte, NC, USA
| | | | - Roger Chammas
- Comprehensive Center for Precision Oncology, Centro de Investigação Translacional em Oncologia (LIM24), Departamento de Radiologia e Oncologia, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Brazil.
| |
Collapse
|
3
|
Jackson JW, Parunov LA, Monteil DT, Ovanesov MV. Effect of wavelength and filter set choices on fluorogenic thrombin generation assay: Considerations for interlaboratory differences. Res Pract Thromb Haemost 2022. [DOI: 10.1002/rth2.12805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Affiliation(s)
- Joseph W. Jackson
- Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
| | - Leonid A. Parunov
- Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
| | - Dominique T. Monteil
- Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
| | - Mikhail V. Ovanesov
- Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
| |
Collapse
|
4
|
Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added Value of Blood Cells in Thrombin Generation Testing. Thromb Haemost 2021; 121:1574-1587. [PMID: 33742437 DOI: 10.1055/a-1450-8300] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The capacity of blood to form thrombin is a critical determinant of coagulability. Plasma thrombin generation (TG), a test that probes the capacity of plasma to form thrombin, has improved our knowledge of the coagulation system and shows promising utility in coagulation management. Although plasma TG gives comprehensive insights into the function of pro- and anticoagulation drivers, it does not measure the role of blood cells in TG. In this literature review, we discuss currently available continuous TG tests that can reflect the involvement of blood cells in coagulation, in particular the fluorogenic assays that allow continuous measurement in platelet-rich plasma and whole blood. We also provide an overview about the influence of blood cells on blood coagulation, with emphasis on the direct influence of blood cells on TG. Platelets accelerate the initiation and velocity of TG by phosphatidylserine exposure, granule content release and surface receptor interaction with coagulation proteins. Erythrocytes are also major providers of phosphatidylserine, and erythrocyte membranes trigger contact activation. Furthermore, leukocytes and cancer cells may be important players in cell-mediated coagulation because, under certain conditions, they express tissue factor, release procoagulant components and can induce platelet activation. We argue that testing TG in the presence of blood cells may be useful to distinguish blood cell-related coagulation disorders. However, it should also be noted that these blood cell-dependent TG assays are not clinically validated. Further standardization and validation studies are needed to explore their clinical usefulness.
Collapse
Affiliation(s)
- Jun Wan
- Synapse Research Institute, Maastricht, The Netherlands.,Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | - Joke Konings
- Synapse Research Institute, Maastricht, The Netherlands.,Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | - Bas de Laat
- Synapse Research Institute, Maastricht, The Netherlands.,Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | - Tilman M Hackeng
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | - Mark Roest
- Synapse Research Institute, Maastricht, The Netherlands.,Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
5
|
Chang WC, Jackson JW, Machlus KR, Wolberg AS, Ovanesov MV. Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples. Res Pract Thromb Haemost 2021; 5:447-455. [PMID: 33870030 PMCID: PMC8035796 DOI: 10.1002/rth2.12499] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 02/01/2021] [Accepted: 02/07/2021] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION The thrombin generation (TG) test is a global hemostasis assay sensitive to procoagulant conditions. However, some TG assays may underestimate elevated TG when the thrombin fluorogenic substrate is depleted or fluorescence is attenuated by the inner filter effect (IFE). OBJECTIVES We sought to elucidate the extent to which procoagulant conditions require correcting for fluorogenic substrate depletion and/or IFE. METHODS We analyzed corrections for substrate depletion and IFE and their effect on TG parameters in plasma samples with elevated blood coagulation factors in the presence or absence of thrombomodulin via commercial calibrated automated thrombogram (CAT) platform and in-house software capable of internal thrombin calibration with or without CAT-like artifact correction. RESULTS Elevated thrombin peak height (TPH) and endogenous thrombin potential (ETP) were detected with 2× and 4× increases in blood coagulation factors I, V, VIII, IX, X, and XI, or prothrombin in the presence or absence of artifact correction. The effect of the CAT algorithm was evident in TG curves from both low procoagulant (thrombomodulin-supplemented) and procoagulant (factor-supplemented) plasma samples. However, in all samples, with the exception of elevated prothrombin, CAT's correction was small (<10%) and did not affect detection of procoagulant samples versus normal plasma. For elevated prothrombin samples, uncorrected TPH or ETP values were underestimated, and CAT correction produced drastically elevated TG curves. CONCLUSIONS Our data suggest that correction for substrate consumption and IFE, as offered by the CAT algorithm, is critical for detecting a subset of extremely procoagulant samples, such as elevated prothrombin, but is not necessary for all other conditions, including elevated factors XI and VIII.
Collapse
Affiliation(s)
- William C. Chang
- Office of Tissues and Advanced TherapiesCenter for Biologics Evaluation and ResearchUS Food and Drug AdministrationSilver SpringMDUSA
| | - Joseph W. Jackson
- Office of Tissues and Advanced TherapiesCenter for Biologics Evaluation and ResearchUS Food and Drug AdministrationSilver SpringMDUSA
| | - Kellie R. Machlus
- Department of Pathology and Laboratory Medicine and UNC Blood Research CenterUniversity of North Carolina at Chapel HillChapel HillNorth CarolinaUSA
- Vascular Biology Program, Department of SurgeryBoston Children's Hospital and Harvard Medical SchoolBostonMAUSA
- Present address:
Brigham and Women’s HospitalHarvard Medical SchoolBostonMAUSA
| | - Alisa S. Wolberg
- Department of Pathology and Laboratory Medicine and UNC Blood Research CenterUniversity of North Carolina at Chapel HillChapel HillNorth CarolinaUSA
| | - Mikhail V. Ovanesov
- Office of Tissues and Advanced TherapiesCenter for Biologics Evaluation and ResearchUS Food and Drug AdministrationSilver SpringMDUSA
| |
Collapse
|
6
|
Comparative Analysis of Thrombin Calibration Algorithms and Correction for Thrombin-α2macroglobulin Activity. J Clin Med 2020; 9:jcm9103077. [PMID: 32987791 PMCID: PMC7650706 DOI: 10.3390/jcm9103077] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/18/2020] [Accepted: 09/22/2020] [Indexed: 12/27/2022] Open
Abstract
Background: The thrombin generation (TG) test is useful for characterizing global hemostasis potential, but fluorescence substrate artifacts, such as thrombin-α2macroglobulin (T-α2MG) signal, inner filter effect (IFE), substrate consumption, and calibration algorithms have been suggested as sources of intra- and inter-laboratory variance, which may limit its clinical utility. Methods: Effects of internal vs. external normalization, IFE and T-α2MG on TG curves in normal plasma supplemented with coagulation factors, thrombomodulin, and tissue factor were studied using the Calibrated Automated Thrombinography (CAT; Diagnostica Stago, Parsippany, NJ, USA) and in-house software. Results: The various calibration methods demonstrated no significant difference in producing TG curves, nor increased the robustness of the TG assay. Several TG parameters, including thrombin peak height (TPH), produced from internal linear calibration did not differ significantly from uncalibrated TG parameters. Further, TPH values from internal linear and nonlinear calibration with or without T-α2MG correction correlated well with TPH from external calibration. Higher coefficients of variation (CVs) for TPH values were observed in both platelet-free and platelet-rich plasma with added thrombomodulin. Conclusions: Our work suggests minimal differences between distinct computational approaches toward calibrating and correcting fluorescence signals into TG levels, with most samples returning similar or equivalent TPH results.
Collapse
|
7
|
Edwards JV, Graves E, Prevost N, Condon B, Yager D, Dacorta J, Bopp A. Development of a Nonwoven Hemostatic Dressing Based on Unbleached Cotton: A De Novo Design Approach. Pharmaceutics 2020; 12:pharmaceutics12070609. [PMID: 32629845 PMCID: PMC7407894 DOI: 10.3390/pharmaceutics12070609] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 06/17/2020] [Accepted: 06/22/2020] [Indexed: 02/07/2023] Open
Abstract
Minimally processed greige (unbleached) cotton fibers demonstrate enhanced clotting relative to highly processed United States Pharmacopeia (USP) type 7 bleached cotton gauze. This effect is thought to be due to the material surface polarity. We hypothesized that a textile could be constructed, conserving the hemostasis-accelerating properties of greige cotton, while maintaining structural integrity and improving absorbance. Spun bond nonwovens of varying surface polarity were designed and prepared based on ratios of greige cotton/bleached cotton/polypropylene fibers. A thromboelastographic analysis was performed on fibrous samples in citrated blood to evaluate the rate of fibrin and clot formation. Lee White clotting times were obtained to assess the material’s clotting activity in platelet fresh blood. An electrokinetic analysis of samples was performed to analyze for material surface polarity. Hemostatic properties varied with composition ratios, fiber density, and fabric fenestration. The determinations of the surface polarity of cotton fabrics with electrokinetic analysis uncovered a range of surface polarities implicated in fabric-initiated clotting; a three-point design approach was employed with the combined use of thromboelastography, thrombin velocity index, Lee White clotting, and absorption capacity determinations applied to fabric structure versus function analysis. The resulting analysis demonstrates that greige cotton may be utilized, along with hydrophilic and hydrophobic fibers, to improve the initiation of fibrin formation and a decrease in clotting time in hemostatic dressings suitable to be commercially developed. Hydroentanglement is an efficient and effective process for imparting structural integrity to cotton-based textiles, while conserving hemostatic function.
Collapse
Affiliation(s)
- J. Vincent Edwards
- Southern Regional Research Center, New Orleans, LA 70124, USA; (E.G.); (N.P.); (B.C.)
- Correspondence: ; Tel.: +1-504-284-4360
| | - Elena Graves
- Southern Regional Research Center, New Orleans, LA 70124, USA; (E.G.); (N.P.); (B.C.)
| | - Nicolette Prevost
- Southern Regional Research Center, New Orleans, LA 70124, USA; (E.G.); (N.P.); (B.C.)
| | - Brian Condon
- Southern Regional Research Center, New Orleans, LA 70124, USA; (E.G.); (N.P.); (B.C.)
| | - Dorne Yager
- Plastic and Reconstructive Surgery, Virginia Commonwealth University, Richmond, VA 23111, USA;
| | | | - Alvin Bopp
- Department of Natural Sciences, Southern University at New Orleans, New Orleans, LA 70126, USA;
| |
Collapse
|
8
|
Gruzdeva O, Uchasova E, Fanaskova E, Akbasheva O, Penskaya T, Plotnikov G, Dyleva Y, Barbarash O. Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. Clin Hemorheol Microcirc 2017; 66:57-66. [PMID: 28128747 PMCID: PMC5438468 DOI: 10.3233/ch-160216] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
To evaluate the parameters of the thrombin generation test (TGT) in coronary artery disease (CAD) patients on prolonged aspirin therapy during on-pump coronary artery bypass grafting (CABG) after donor platelet concentrate transfusion. A total of 148 patients with CAD on prolonged aspirin therapy (75–100 mg/day) who have undergone elective on-pump CABG were consecutively included in the study. Patients were divided randomly into two groups. Group 1 (n = 76) received donor platelet transfusions after cardiopulmonary bypass, whereas Group 2 (n = 72) did not. TGT parameters were measured using an analyzer at pre-, intra-, and early postoperative periods. Activation of the endogenous thrombin potential was observed in patients on prolonged aspirin therapy in the pre- and intraoperative periods, as confirmed by high peak thrombin and increased velocity index. The activation time of the prothrombinase complex and thrombin generation time were greater than the control group. The blood hemostatic potential in patients who did not receive transfusions in the early postoperative period decreased up to the level of the control group in the extended time parameters. Hemostatic potential in plasma in patients on aspirin was preserved. Given the laboratory test results and clinical data, platelet concentrate transfusion is unnecessary for prevention.
Collapse
Affiliation(s)
- Olga Gruzdeva
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Evgenya Uchasova
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Elena Fanaskova
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Olga Akbasheva
- Federal State Budget Educational Institution of Higher Professional Education "Siberian StateMedical University", the Ministry of Health of the Russian Federation, Tomsk, Russia
| | - Tatyana Penskaya
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Georgy Plotnikov
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Yulia Dyleva
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
| | - Olga Barbarash
- Federal State Budgetary Institution "Research Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia.,Federal State Budget Educational Institution of Higher Professional Education "Kemerovo State Medical University", the Ministry of Health of the Russian Federation, Kemerovo, Russia
| |
Collapse
|
9
|
Ramjee MK, Patel S. Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition. Anal Biochem 2017; 528:38-46. [PMID: 28456636 DOI: 10.1016/j.ab.2017.04.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 04/24/2017] [Accepted: 04/25/2017] [Indexed: 01/28/2023]
Abstract
A microfluidic assay for monitoring the inhibition of thrombin peptidase activity was developed. The system, which utilised soluble reagents in continuous-flow injection mode, was configured so as to allow inhibitor titrations via gradient formation. This microfluidic continuous-flow injection titration assay (CFITA) enabled the potency of a set of small-molecule serine peptidase inhibitors (SPIs) to be evaluated. The results, compared to standard microtiter plate (MTP) data, indicated that a microfluidic CFITA provided an efficient and effective method for evaluating compound potency. Crucially, whereas for fast-acting compounds the rank order of potency between the CFITA and MTP methods was preserved, for slow-acting compounds the observed CFITA potencies were significantly lower. These results, in conjunction with data from computer simulations, clearly demonstrated that continuous-flow assays, and perhaps microfluidic assays in general, must take into account binding kinetics when used to assess reaction criteria.
Collapse
Affiliation(s)
- Manoj K Ramjee
- Cyclofluidic Limited, BioPark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom.
| | - Sital Patel
- Cyclofluidic Limited, BioPark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom
| |
Collapse
|
10
|
Calpain-controlled detachment of major glycoproteins from the cytoskeleton regulates adhesive properties of activated phosphatidylserine-positive platelets. Biochem J 2015; 473:435-48. [PMID: 26607836 DOI: 10.1042/bj20150779] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 11/25/2015] [Indexed: 12/17/2022]
Abstract
In resting platelets, adhesive membrane glycoproteins are attached to the cytoskeleton. On strong activation, phosphatidylserine(PS)-positive and -negative platelet subpopulations are formed. Platelet activation is accompanied by cytoskeletal rearrangement, although the glycoprotein attachment status in these two subpopulations is not clear. We developed a new, flow cytometry-based, single-cell approach to investigate attachment of membrane glycoproteins to the cytoskeleton in cell subpopulations. In PS-negative platelets, adhesive glycoproteins integrin αIIbβ3, glycoprotein Ib and, as shown for the first time, P-selectin were associated with the cytoskeleton. In contrast, this attachment was disrupted in PS-positive platelets; it was retained to some extent only in the small convex regions or 'caps'. It correlated with the degradation of talin and filamin observed only in PS-positive platelets. Calpain inhibitors essentially prevented the disruption of membrane glycoprotein attachment in PS-positive platelets, as well as talin and filamin degradation. With the suggestion that detachment of glycoproteins from the cytoskeleton may affect platelet adhesive properties, we investigated the ability of PS-positive platelets to resist shear-induced breakaway from the immobilized fibrinogen. Shear rates of 500/s caused PS-positive platelet breakaway, but their adhesion stability increased more than 10-fold after pretreatment of the platelets with calpain inhibitor. In contrast, the ability of PS-positive platelets to adhere to immobilized von Willebrand's factor at 100/s was low, but this was not affected by the preincubation of platelets with a calpain inhibitor. Our data suggest that calpain-controlled detachment of membrane glycoproteins is a new mechanism that is responsible for the loss of ability of the procoagulant platelets to resist detachment from thrombi by high shear stress.
Collapse
|
11
|
Zakharova NV, Artemenko EO, Podoplelova NA, Sveshnikova AN, Demina IA, Ataullakhanov FI, Panteleev MA. Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII. PLoS One 2015; 10:e0116665. [PMID: 25688860 PMCID: PMC4331558 DOI: 10.1371/journal.pone.0116665] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Accepted: 12/11/2014] [Indexed: 01/23/2023] Open
Abstract
Coagulation factor XII (fXII) is important for arterial thrombosis, but its physiological activation mechanisms are unclear. In this study, we elucidated the role of platelets and platelet-derived material in fXII activation. FXII activation was only observed upon potent platelet stimulation (with thrombin, collagen-related peptide, or calcium ionophore, but not ADP) accompanied by phosphatidylserine exposure and was localised to the platelet surface. Platelets from three patients with grey platelet syndrome did not activate fXII, which suggests that platelet-associated fXII-activating material might be released from α-granules. FXII was preferentially bound by phosphotidylserine-positive platelets and annexin V abrogated platelet-dependent fXII activation; however, artificial phosphotidylserine/phosphatidylcholine microvesicles did not support fXII activation under the conditions herein. Confocal microscopy using DAPI as a poly-phosphate marker did not reveal poly-phosphates associated with an activated platelet surface. Experimental data for fXII activation indicates an auto-inhibition mechanism (ki/ka = 180 molecules/platelet). Unlike surface-associated fXII activation, platelet secretion inhibited activated fXII (fXIIa), particularly due to a released C1-inhibitor. Platelet surface-associated fXIIa formation triggered contact pathway-dependent clotting in recalcified plasma. Computer modelling suggests that fXIIa inactivation was greatly decreased in thrombi under high blood flow due to inhibitor washout. Combined, the surface-associated fXII activation and its inhibition in solution herein may be regarded as a flow-sensitive regulator that can shift the balance between surface-associated clotting and plasma-dependent inhibition, which may explain the role of fXII at high shear and why fXII is important for thrombosis but negligible in haemostasis.
Collapse
Affiliation(s)
- Natalia V. Zakharova
- National Research Center for Hematology, Moscow, Russia
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Elena O. Artemenko
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Nadezhda A. Podoplelova
- National Research Center for Hematology, Moscow, Russia
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Anastasia N. Sveshnikova
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
- Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia
| | - Irina A. Demina
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Fazly I. Ataullakhanov
- National Research Center for Hematology, Moscow, Russia
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
- Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia
- Faculty of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
| | - Mikhail A. Panteleev
- National Research Center for Hematology, Moscow, Russia
- Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
- Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
- Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia
- Faculty of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
- * E-mail:
| |
Collapse
|
12
|
Gu JM, Ramsey P, Evans V, Tang L, Apeler H, Leong L, Murphy JE, Laux V, Myles T. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20:593-600. [DOI: 10.1111/hae.12374] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2013] [Indexed: 01/19/2023]
Affiliation(s)
- J-M. Gu
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - P. Ramsey
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - V. Evans
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - L. Tang
- Biological Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - H. Apeler
- Biological Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - L. Leong
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - J. E. Murphy
- Biological Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - V. Laux
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| | - T. Myles
- Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA
| |
Collapse
|
13
|
Mitchell JA, Nagymihaly R, Uhrinyi OM, Harsfalvi J. Measurement of thrombin in different matrices: whole blood, platelet-rich and platelet-poor plasma using fluorogenic substrate ZGGR-AMC. Acta Haematol 2013; 130:150-2. [PMID: 23689593 DOI: 10.1159/000347179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Accepted: 01/14/2013] [Indexed: 11/19/2022]
Affiliation(s)
- Joel A Mitchell
- Clinical Research Center, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | | | | | | |
Collapse
|
14
|
Han D, Zhu Z, Wu C, Peng L, Zhou L, Gulbakan B, Zhu G, Williams KR, Tan W. A logical molecular circuit for programmable and autonomous regulation of protein activity using DNA aptamer-protein interactions. J Am Chem Soc 2012. [PMID: 23194304 DOI: 10.1021/ja310428s] [Citation(s) in RCA: 101] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Researchers increasingly envision an important role for artificial biochemical circuits in biological engineering, much like electrical circuits in electrical engineering. Similar to electrical circuits, which control electromechanical devices, biochemical circuits could be utilized as a type of servomechanism to control nanodevices in vitro, monitor chemical reactions in situ, or regulate gene expressions in vivo. (1) As a consequence of their relative robustness and potential applicability for controlling a wide range of in vitro chemistries, synthetic cell-free biochemical circuits promise to be useful in manipulating the functions of biological molecules. Here, we describe the first logical circuit based on DNA-protein interactions with accurate threshold control, enabling autonomous, self-sustained and programmable manipulation of protein activity in vitro. Similar circuits made previously were based primarily on DNA hybridization and strand displacement reactions. This new design uses the diverse nucleic acid interactions with proteins. The circuit can precisely sense the local enzymatic environment, such as the concentration of thrombin, and when it is excessively high, a coagulation inhibitor is automatically released by a concentration-adjusted circuit module. To demonstrate the programmable and autonomous modulation, a molecular circuit with different threshold concentrations of thrombin was tested as a proof of principle. In the future, owing to tunable regulation, design modularity and target specificity, this prototype could lead to the development of novel DNA biochemical circuits to control the delivery of aptamer-based drugs in smart and personalized medicine, providing a more efficient and safer therapeutic strategy.
Collapse
Affiliation(s)
- Da Han
- Department of Chemistry, Center for Research at the Bio/Nano Interface, Shands Cancer Center and UF Genetics Institute, University of Florida, Gainesville, Florida 32611-7200, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Topalov NN, Yakimenko AO, Canault M, Artemenko EO, Zakharova NV, Abaeva AA, Loosveld M, Ataullakhanov FI, Nurden AT, Alessi MC, Panteleev MA. Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin α
IIb
β
3. Arterioscler Thromb Vasc Biol 2012; 32:2475-83. [DOI: 10.1161/atvbaha.112.253765] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Phosphatidylserine (PS) externalization by platelets upon activation is a key event in hemostasis and thrombosis. It is currently believed that strong stimulation of platelets forms 2 subpopulations, only 1 of which expresses PS.
Methods and Results—
Here, we demonstrate that physiological stimulation leads to the formation of not 1 but 2 types of PS-expressing activated platelets, with dramatically different properties. One subpopulation sustained increased calcium level after activation, whereas another returned to the basal low-calcium state. High-calcium PS-positive platelets had smaller size, high surface density of fibrin(ogen), no active integrin α
IIb
β
3
, depolarized mitochondrial membranes, gradually lost cytoplasmic membrane integrity, and were poorly aggregated. In contrast, the low-calcium PS-positive platelets had normal size, retained mitochondrial membrane potential and cytoplasmic membrane integrity, and combined retention of fibrin(ogen) with active α
IIb
β
3
and high proaggregatory function. Formation of low-calcium PS-positive platelets was promoted by platelet concentration increase or shaking and was decreased by integrin α
IIb
β
3
antagonists, platelet dilution, or in platelets from kindlin-3–deficient and Glanzmann thrombasthenia patients.
Conclusion—
Identification of a novel PS-expressing platelet subpopulation with low calcium regulated by integrin α
IIb
β
3
can be important for understanding the mechanisms of PS exposure and thrombus formation.
Collapse
Affiliation(s)
- Nikolay N. Topalov
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Alena O. Yakimenko
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Matthias Canault
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Elena O. Artemenko
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Natalia V. Zakharova
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Anastasia A. Abaeva
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Marie Loosveld
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Fazoil I. Ataullakhanov
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Alan T. Nurden
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Marie-Christine Alessi
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| | - Mikhail A. Panteleev
- From the Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia (N.N.T., E.O.A., N.V.Z., A.A.A., F.I.A., M.A.P.); HemaCore LLC, Moscow, Russia (A.O.Y., F.I.A., M.A.P.); Université de la Méditerranée, Marseille Cedex, France (M.C., M.L., M-C.A.); INSERM Unité Mixte de Recherche, Marseille Cedex, France (M.C., M.L., M-C.A.); Laboratoire d’Hématologie, Hôpital de la Timone, Marseille Cedex, France (M.C., M.L., M-C.A.); National Research Centre for Hematology, Moscow, Russia (F
| |
Collapse
|
16
|
Li N. Reversible regulation of aptamer activity with effector-responsive hairpin oligonucleotides. ACTA ACUST UNITED AC 2012; 18:77-84. [PMID: 22651934 DOI: 10.1177/2211068212448429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aptamers are oligonucleotides that can bind to various nonnucleic acid molecular targets in a high affinity and specificity. As an emerging class of therapeutic agents, aptamers offer an unparalleled advantage over other classes of therapeutic agents: the possibility to rationally regulate the therapeutic activity of aptamers. Most existing strategies for regulating the aptamer activity have a limited specificity and/or reversibility. Herein we report a simple, generic strategy to simultaneously achieve specificity and reversibility by exploiting the spontaneous conformational change of hairpin oligonucleotides upon the specific recognition of nucleic acid effectors. The effector-responsive hairpin oligonucleotide consists of a sensing loop that recognizes a particular nucleic acid effector, an aptamer stem that inhibits a certain therapeutic target, and an antidote stem that is complementary to the aptamer. Upon the introduction/removal of the effector, the hairpin oligonucleotide undergoes a conformational change that activates/deactivates the aptamer's inhibiting activity on the therapeutic target. This new strategy has been demonstrated with an anticoagulant aptamer that binds and inhibits human α-thrombin.
Collapse
Affiliation(s)
- Na Li
- Department of Mechanical & Aerospace Engineering, University of Miami, Coral Gables, FL 33146, USA.
| |
Collapse
|
17
|
van Berkel SS, van der Lee B, van Delft FL, Wagenvoord R, Hemker HC, Rutjes FPJT. Fluorogenic peptide-based substrates for monitoring thrombin activity. ChemMedChem 2012; 7:606-17. [PMID: 22294421 DOI: 10.1002/cmdc.201100560] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Revised: 01/02/2012] [Indexed: 11/11/2022]
Abstract
The synthesis of a series of peptides containing C-terminal 7-amino-4-methylcoumarin (AMC) for use in the thrombin generation test (TGT) is described. The lead structure in this project was H-Gly-Gly-Arg-AMC, of which the water solubility and kinetic parameters (K(M) and k(cat)) are greatly improved over those of the substrate in current use in the TGT: Cbz-Gly-Gly-Arg-AMC. A series of N-terminally substituted Gly-Gly-Arg-AMC derivatives were synthesized, as well as implementation of structural changes at either the P(2) or P(3) position of the peptide backbone. Furthermore, two substrates were synthesized that have structural similarities to the chromogenic thrombin substrate SQ68 or that contain a 1,2,3-triazole moiety in the peptide chain, mimicking an amide bond. To determine the applicability of newly synthesized fluorogenic substrates for monitoring continuous thrombin generation, the K(M) and k(cat) values of the conversion of these fluorogenic substrates by thrombin (FIIa) and factor Xa (FXa) were quantified. An initial selection was made on basis of these data, and suitable substrates were further evaluated as substrates in the thrombin generation assay. Assessment of the acquired data showed that several substrates, including the SQ68 derivative Et-malonate-Gly-Arg-AMC and N-functionalized Gly-Gly-Arg-AMC derivatives, are suitable candidates for replacement of the substrate currently in use.
Collapse
Affiliation(s)
- Sander S van Berkel
- Radboud University Nijmegen, Institute for Molecules and Materials, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|
18
|
Topalov NN, Kotova YN, Vasil’ev SA, Panteleev MA. Identification of signal transduction pathways involved in the formation of platelet subpopulations upon activation. Br J Haematol 2012; 157:105-15. [DOI: 10.1111/j.1365-2141.2011.09021.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res 2012; 129:681-7. [PMID: 22221936 DOI: 10.1016/j.thromres.2011.12.006] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 12/02/2011] [Accepted: 12/04/2011] [Indexed: 10/14/2022]
Abstract
Bleeding and thrombosis are the ultimate clinical outcomes of aberrations in the haemostatic process. Haemostasis prevents excessive blood loss due to the effort of various compartments like the vasculature, blood cells, coagulation and fibrinolysis. The complexity of all processes involved makes the diagnosis of aberrations difficult, cumbersome and expensive. A single assay to detect any factor disturbing this haemostatic balance with high sensitivity and specificity would be of great value, especially if the outcome of this assay correlates well with clinical outcome. Despite years of research, such an assay is not yet available; however, some interesting candidates are under development and combine the effects of various compartments. This review describes the development of global haemostasis assays and summarizes the current state of the art of these haemostasis assays covering thrombin and plasmin generation, turbidity and thromboelastography/thromboelastometry. Finally, we discuss the applicability of global assays in clinical practice and we provide a future perspective on the ongoing development of automation and miniaturisation as it is our belief that these developments will benefit the standardization of global haemostasis assays.
Collapse
Affiliation(s)
- Mark van Geffen
- Laboratory of Haematology, department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
| | | |
Collapse
|
20
|
Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. Blood Coagul Fibrinolysis 2012; 23:98-103. [DOI: 10.1097/mbc.0b013e32834ddf4d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Thrombin production and human neutrophil elastase sequestration by modified cellulosic dressings and their electrokinetic analysis. J Funct Biomater 2011; 2:391-413. [PMID: 24956451 PMCID: PMC4030916 DOI: 10.3390/jfb2040391] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Revised: 12/03/2011] [Accepted: 12/07/2011] [Indexed: 01/01/2023] Open
Abstract
Wound healing is a complex series of biochemical and cellular events. Optimally, functional material design addresses the overlapping acute and inflammatory stages of wound healing based on molecular, cellular, and bio-compatibility issues. In this paper the issues addressed are uncontrolled hemostasis and inflammation which can interfere with the orderly flow of wound healing. In this regard, we review the serine proteases thrombin and elastase relative to dressing functionality that improves wound healing and examine the effects of charge in cotton/cellulosic dressing design on thrombin production and elastase sequestration (uptake by the wound dressing). Thrombin is central to the initiation and propagation of coagulation, and elastase is released from neutrophils that can function detrimentally in a stalled inflammatory phase characteristic of chronic wounds. Electrokinetic fiber surface properties of the biomaterials of this study were determined to correlate material charge and polarity with function relative to thrombin production and elastase sequestration. Human neutrophil elastase sequestration was assessed with an assay representative of chronic wound concentration with cotton gauze cross-linked with three types of polycarboxylic acids and one phosphorylation finish; thrombin production, which was assessed in a plasma-based assay via a fluorogenic peptide substrate, was determined for cotton, cotton-grafted chitosan, chitosan, rayon/polyester, and two kaolin-treated materials including a commercial hemorrhage control dressing (QuickClot Combat Gauze). A correlation in thrombin production to zeta potential was found. Two polycarboxylic acid cross linked and a phosphorylated cotton dressing gave high elastase sequestration.
Collapse
|
22
|
Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Thromb Res 2011; 128:e166-70. [DOI: 10.1016/j.thromres.2011.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2011] [Revised: 07/22/2011] [Accepted: 08/02/2011] [Indexed: 10/17/2022]
|
23
|
Castro-López V, Harris LF, O’Donnell JS, Killard AJ. Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. J Pharm Biomed Anal 2011; 56:992-7. [DOI: 10.1016/j.jpba.2011.07.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2011] [Revised: 07/20/2011] [Accepted: 07/21/2011] [Indexed: 11/24/2022]
|
24
|
Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thromb Haemost 2011; 106:705-11. [PMID: 21833453 DOI: 10.1160/th11-05-0311] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Accepted: 06/30/2011] [Indexed: 11/05/2022]
Abstract
Blood coagulation cascades can be activated by different mechanisms and to different levels in cancer patients. In a study conducted on the transcriptional profile of epithelial ovarian cancer patients a number of possible links between coagulation and inflammation have been suggested and we and others have reported that, in addition to its central role in blood coagulation and haemostasis, thrombin is a powerful regulator of inflammatory responses. Here, we report that thrombin- like activities were present in the malignant ascites of patients with ovarian carcinoma. Malignant ascites significantly enhanced the release of cytokines/chemokines, which have been previously shown to support tumour progression, such as interleukin (IL)-6, IL-1β, CCL2 and CXCL8, in human peripheral blood mononuclear cells of healthy volunteers. Interestingly, ascites enhanced the release of the anti-inflammatory cytokine IL-10 and inhibited the production of interferon-γ and IL-12. The presence of the anticoagulant antithrombin reversed IL-12 inhibition induced by ascites in human monocytes. Finally, the use of thrombin and of the specific thrombin receptor (PAR) agonist peptides, TFLLRN and AYGPK, suggests that IL-12 inhibition is thrombin-specific and related to PAR-1, but not to PAR-4. These findings underline the tight relationship between the coagulation pathway, where thrombin is the key enzyme, and cytokine modulation, including IL-12 inhibition, which is a critical feature of the tumour microenvironment, and may represent a powerful strategy used by tumours to escape immune surveillance.
Collapse
Affiliation(s)
- Antonella Naldini
- Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy.
| | | | | | | | | | | |
Collapse
|
25
|
Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. Anal Bioanal Chem 2010; 399:691-700. [DOI: 10.1007/s00216-010-4314-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2010] [Revised: 10/06/2010] [Accepted: 10/07/2010] [Indexed: 12/23/2022]
|
26
|
Stief TW, Otto S, Renz H. Intrinsic hemostasis activation by freezing and thawing of plasma. Clin Appl Thromb Hemost 2009; 15:59-64. [PMID: 19150993 DOI: 10.1177/1076029607303763] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Low-grade contact activation of hemostasis is clinically relevant. Freezing/thawing of plasma was studied in the intrinsic coagulation activity assay. Normal plasmas were frozen at -80 degrees C or -20 degrees C and thawed at 37 degrees C or 23 degrees C. These plasmas and unfrozen samples were activated by SiO2 -CaCl2. Freezing/thawing of normal plasma induced about 100-fold more thrombin activity at 5 minutes coagulation reaction time than the respective unfrozen samples. Freezing at -80 degrees C induces more artificial changes than freezing at -20 degrees C. In 9 of 10 plasmas of patients receiving coumarin, nearly no additional thrombin is generated within a 12-minute coagulation reaction time. Minor procoagulant changes of plasma might be dangerous in patients with insufficient liver function, who might not tolerate a therapy with fresh frozen plasma, which behaves as a procoagulant because of its matrix changes. The intrinsic coagulation activity assay allows the measurement of low-grade contact activation of frozen/thawed plasma.
Collapse
Affiliation(s)
- Thomas W Stief
- Department of Clinical Chemistry, University Hospital Giessen & Marburg, Germany.
| | | | | |
Collapse
|
27
|
van Berkel SS, van der Lee B, van Delft FL, Rutjes FPJT. A macrocyclic coumarin-containing tripeptide via CuAAC chemistry. Chem Commun (Camb) 2009:4272-4. [DOI: 10.1039/b906762k] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
28
|
van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142:889-903. [PMID: 18564356 DOI: 10.1111/j.1365-2141.2008.07267.x] [Citation(s) in RCA: 160] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Thrombin is the central enzyme in the coagulation cascade. Estimation of an individual's potential to generate thrombin may correlate more closely with a hyper- or hypo-coagulable phenotype, compared to traditional coagulation tests. The possible correlation and recent technical advances in thrombin generation measurement has caused a significant interest in the method and the development of commercial assays. Several variations of the assay exist depending on the defect to be investigated. Fluorogenic thrombin generation assays have acceptable intra-laboratory variation but a higher inter-laboratory variation. Variation in preanalytical variables makes comparisons between studies difficult. Thrombin generation is highly variable between individuals and there are suggestions that this may allow individualized treatment based on global haemostatic response in patients with bleeding disorders or on anticoagulant therapy. In patients with thrombotic disorders it may be possible to identify those at higher risk of recurrent thrombosis. For both scenarios, however, data from large prospective studies are lacking or inconclusive and a good relationship between thrombin generation and phenotype remains to be established. Further standardization of the assay is needed before large multicentre studies can be conducted and until then thrombin generation in routine clinical practice is not yet a reality.
Collapse
Affiliation(s)
- J J van Veen
- Leicester Haemophilia Comprehensive Care Centre & Haemostasis and Thrombosis Unit, Leicester, UK.
| | | | | |
Collapse
|
29
|
Abstract
The appropriate development of hemostasis encompasses a delicate equilibrium between anti- and prothrombotic forces developing during three distinct phases (primary hemostasis, coagulation and fibrinolysis) that are closely linked to each other and precisely regulated to close vessel wounds, promote vascular healing and maintain vessel patency. Imbalance in each of these systems produces either hemorrhagic or thrombotic disorders. Inherited bleeding disorders, caused by quantitative or qualitative alterations of either platelets or plasma proteins involved in blood coagulation and fibrinolysis, may lead to serious and lifelong bleeding conditions, the severity of which is inversely associated with the degree of the underlying defect. Rapid and reliable identification of these pathologies is worthy of focus to allow the adoption of appropriate substitutive or supportive antihemorrhagic therapies. Evaluation of the hemorrhage-prone patient requires careful recording of the medical history, attention to pertinent physical findings and the discretionary use of laboratory resources. Owing to the low diagnostic efficiency of clinical history and examination, an appropriate and reliable laboratory approach, encompassing first- and second-line testing, is essential to screen, diagnose and monitor patients with bleeding diatheses. As both the analytical sensitivity and responsiveness of traditional coagulation assays to different abnormalities differ widely, each laboratory should establish individual guidelines based on field experience and on reagent and instrument characteristics. Emerging evidence indicates that the implementation of global coagulation tests, such as the thrombin generation assay and clot waveform analysis, would provide additional information for clinical decision-making for patients with inherited bleeding disorders.
Collapse
Affiliation(s)
- Giuseppe Lippi
- Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy.
| | | | | |
Collapse
|
30
|
Song H, Li HW, Munson MS, Van Ha TG, Ismagilov RF. On-chip titration of an anticoagulant argatroban and determination of the clotting time within whole blood or plasma using a plug-based microfluidic system. Anal Chem 2006; 78:4839-49. [PMID: 16841902 PMCID: PMC1851927 DOI: 10.1021/ac0601718] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
This paper describes extending plug-based microfluidics to handling complex biological fluids such as blood, solving the problem of injecting additional reagents into plugs, and applying this system to measuring of clotting time in small volumes of whole blood and plasma. Plugs are droplets transported through microchannels by fluorocarbon fluids. A plug-based microfluidic system was developed to titrate an anticoagulant (argatroban) into blood samples and to measure the clotting time using the activated partial thromboplastin time (APTT) test. To carry out these experiments, the following techniques were developed for a plug-based system: (i) using Teflon AF coating on the microchannel wall to enable formation of plugs containing blood and transport of the solid fibrin clots within plugs, (ii) using a hydrophilic glass capillary to enable reliable merging of a reagent from an aqueous stream into plugs, (iii) using bright-field microscopy to detect the formation of a fibrin clot within plugs and using fluorescent microscopy to detect the production of thrombin using a fluorogenic substrate, and (iv) titration of argatroban (0-1.5 microg/mL) into plugs and measurement of the resulting APTTs at room temperature (23 degrees C) and physiological temperature (37 degrees C). APTT measurements were conducted with normal pooled plasma (platelet-poor plasma) and with donor's blood samples (both whole blood and platelet-rich plasma). APTT values and APTT ratios measured by the plug-based microfluidic device were compared to the results from a clinical laboratory at 37 degrees C. APTT obtained from the on-chip assay were about double those from the clinical laboratory but the APTT ratios from these two methods agreed well with each other.
Collapse
|
31
|
Petros S, Siegemund T, Siegemund A, Engelmann L. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis 2006; 17:131-7. [PMID: 16479195 DOI: 10.1097/01.mbc.0000214708.73374.ce] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Decrease in thrombin generation is the key effect in anticoagulation. The aim of the present study was to investigate the effect of anticoagulants on thrombin generation and the relation to platelet count. Plasma samples from 10 healthy volunteers (mean age 43.0 +/- 9 years) were incubated at preset platelet counts with different doses of the anticoagulants lepirudin, fondaparinux and low molecular weight heparins. Thrombin generation was measured in a tissue factor-mediated assay using a fluorometer and a slow-reacting fluorogenic substrate. The endogenous thrombin potential, the lag phase, the maximum reaction velocity (Vmax) and the concentration of a given anticoagulant required for 50% inhibition of thrombin generation (IC50) are presented. All three anticoagulants decreased endogenous thrombin potential and prolonged the lag phase in a dose-dependent manner. Fondaparinux and low molecular weight heparins, but not hirudin, decreased Vmax in a concentration-dependent manner. With increasing platelet count, the IC50 increased but the extent of this increase was not uniform for the three anticoagulants and the three variables investigated. The influence of anticoagulants on thrombin generation is variable, depending on their basic mechanism of action. In defining and comparing their effects, the endogenous thrombin potential, the lag phase and the maximum reaction velocity should be considered together. Platelets have a considerable influence on the magnitude of thrombin generation.
Collapse
Affiliation(s)
- Sirak Petros
- University of Leipzig, Centre of Internal Medicine, Clinical Haemostaseology and Adult Haemophilia Centre, Leipzig, Germany.
| | | | | | | |
Collapse
|
32
|
Garden SR, Doellgast GJ, Killham KS, Strachan NJC. A fluorescent coagulation assay for thrombin using a fibre optic evanescent wave sensor. Biosens Bioelectron 2004; 19:737-40. [PMID: 14709392 DOI: 10.1016/j.bios.2003.08.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A fibre optic evanescent wave sensor is used for the rapid detection of thrombin. Coagulation of solution phase fluorescently labelled fibrinogen to unlabelled fibrinogen bound to the surface of the fibre optic is observed in real time by the evanescent wave sensor. Thrombin concentrations down to 0.01 NIHml(-1) are detectable within 5 min. The potential application of this technique for rapid amplified immunosensing is discussed.
Collapse
Affiliation(s)
- Steven R Garden
- Department of Plant, Soil Science, School of Biological Sciences, Cruickshank Building, University of Aberdeen, Aberdeen AB24 3UU, UK
| | | | | | | |
Collapse
|
33
|
Keuren JFW, Ulrichts H, Feijge MAH, Hamulyak K, Deckmyn H, Lindhout T, Heemskerk JWM. Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma. THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE 2003; 141:350-8. [PMID: 12761479 DOI: 10.1016/s0022-2143(03)00004-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Under conditions of arterial-wall shear rates, platelets bind to von Willebrand factor (vWf) by way of the glycoprotein Ib (GP Ib) complex and integrin alpha(IIb)beta(3). Both adhesive receptors may also play roles in the development of procoagulant activity of platelets. Here, we investigated the effect of shear stress, as provided by a rotating cylinder, on GP Ib- and integrin alpha(IIb)beta(3)-dependent thrombin generation in coagulating platelet-rich plasma (PRP). We measured thrombin continuously with the use of fluorometry from the cleavage rate of a fluorescent low-affinity substrate. The integrin alpha(IIb)beta(3) antagonist abciximab progressively reduced the peak of thrombin formation up to 43% when rate of stirring and shear stress were increased (estimated shear rates of 105-420 s(-1)). Abciximab did not lower the peak of thrombin formation in stirred PRP from patients with Glanzmann's thrombasthenia lacking alpha(IIb)beta(3) but, surprisingly, shortened the time until onset. In PRP from control subjects, antibodies specifically directed against vWf-binding epitopes on GP Ibalpha reduced thrombin formation, with 25% to 30% at the high but not at the low stirring rate. In combination with the anti-GP Ib antibody, abciximab retained its strong inhibitory effect only at the high stirring rate. We conclude that thrombin formation and coagulation in stirred PRP depend, to a large extent, on platelet adhesion to integrin alpha(IIb)beta(3) and, in a shear-dependent way, on GP Ib.
Collapse
Affiliation(s)
- Jeffrey F W Keuren
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
34
|
Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem 2002; 277:50439-44. [PMID: 12496240 DOI: 10.1074/jbc.m208222200] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The present study began with mathematical modeling of how inhibitors of both factor Xa (fXa) and thrombin affect extrinsic pathway-triggered blood coagulation. Numerical simulation demonstrated a stronger inhibition of thrombin generation by a thrombin inhibitor than a fXa inhibitor, but both prolonged clot time to a similar extent when they were given an equal dissociation constant (30 nm) for interaction with their respective target enzymes. These differences were then tested by comparison with the real inhibitors DX-9065a and argatroban, specific competitive inhibitors of fXa and thrombin, respectively, with similar K(i) values. Comparisons were made in extrinsically triggered human citrated plasma, for which endogenous thrombin potential and clot formation were simultaneously measured with a Wallac multilabel counter equipped with both fluorometric and photometric detectors and a fluorogenic reporter substrate. The results demonstrated stronger inhibition of endogenous thrombin potential by argatroban than by DX-9065a, especially when coagulation was initiated at higher tissue factor concentrations, while argatroban appeared to be slightly less potent in its ability to prolong clot time. This study demonstrates differential inhibition of thrombin generation by fXa and thrombin inhibitors and has implications for the pharmacological regulation of blood coagulation by the anticoagulant protease inhibitors.
Collapse
Affiliation(s)
- Hajime Nagashima
- New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Tokyo 104-8369, Japan.
| |
Collapse
|